The aim of this study is to establish the safe and effective ocular delivery system of therapeutic small interfering RNA (siRNA) in corneal neovascularization therapy. The major hurdle present in siRNA-based corneal neovascularization (CNV) therapy is severe cytotoxicity caused by repetitive drug treatment. A reducible branched polyethylenimine (rBPEI)-based nanoparticle (NP) system is utilized as a new siRNA carrier as a hope for CNV therapy. The thiolated BPEI is readily self-crosslinked in mild conditions to make high molecular weight rBPEI thus allowing the creation of stable siRNA/rBPEI nanoparticles (siRNA-rBPEI-NPs). In the therapeutic region, the rBPEI polymeric matrix is effectively degraded into nontoxic LMW BPEI inside the reduct...
A variety of genetic diseases in the retina, including retinitis pigmentosa and leber congenital ama...
Pathologic neovascularization of the retina is a major cause of substantial and irreversible loss of...
Safe and effective delivery is required for siRNA and mRNA-based therapeutics to reach their potenti...
Gene silencing targeting proangiogenic factors have been shown to be a useful strategy in the treatm...
Abstract Controlling gene expression via small interfering RNA (siRNA) has opened the ...
Clinical translation of polymer-based nanocarriers for systemic delivery of RNA has been limited due...
Background: Choroidal neovascularization (CNV), also known as subretinal neovascularization, causes ...
Recently, we discovered that polyethylenimine-conjugated gold nanoparticles (PEI2- GNP) could be use...
The clinical application of RNA interference (RNAi)-based cancer gene therapy has been hampered by t...
Retinitis pigmentosa (RP) is the most common cause of inherited blindness in adults. Mutations in th...
Drug therapy for retinal diseases (e.g., age-related macular degeneration, the leading cause of blin...
Ophthalmic gene therapy is an intellectual and intentional manipulation of desired gene expression i...
Corneal diseases are the third leading cause of blindness globally. Topical nonsteroidal anti-inflam...
Zhenzhen Liu,1,* Haijun Gong,2,* Rui Zeng,2 Xuan Liang,1 Li-Ming Zhang,1 Liqun Yang,1,* Yuqing Lan2,...
The main cause of subretinal neovascularisation in wet age-related macular degeneration (AMD) is an ...
A variety of genetic diseases in the retina, including retinitis pigmentosa and leber congenital ama...
Pathologic neovascularization of the retina is a major cause of substantial and irreversible loss of...
Safe and effective delivery is required for siRNA and mRNA-based therapeutics to reach their potenti...
Gene silencing targeting proangiogenic factors have been shown to be a useful strategy in the treatm...
Abstract Controlling gene expression via small interfering RNA (siRNA) has opened the ...
Clinical translation of polymer-based nanocarriers for systemic delivery of RNA has been limited due...
Background: Choroidal neovascularization (CNV), also known as subretinal neovascularization, causes ...
Recently, we discovered that polyethylenimine-conjugated gold nanoparticles (PEI2- GNP) could be use...
The clinical application of RNA interference (RNAi)-based cancer gene therapy has been hampered by t...
Retinitis pigmentosa (RP) is the most common cause of inherited blindness in adults. Mutations in th...
Drug therapy for retinal diseases (e.g., age-related macular degeneration, the leading cause of blin...
Ophthalmic gene therapy is an intellectual and intentional manipulation of desired gene expression i...
Corneal diseases are the third leading cause of blindness globally. Topical nonsteroidal anti-inflam...
Zhenzhen Liu,1,* Haijun Gong,2,* Rui Zeng,2 Xuan Liang,1 Li-Ming Zhang,1 Liqun Yang,1,* Yuqing Lan2,...
The main cause of subretinal neovascularisation in wet age-related macular degeneration (AMD) is an ...
A variety of genetic diseases in the retina, including retinitis pigmentosa and leber congenital ama...
Pathologic neovascularization of the retina is a major cause of substantial and irreversible loss of...
Safe and effective delivery is required for siRNA and mRNA-based therapeutics to reach their potenti...